<DOC>
	<DOCNO>NCT02694523</DOCNO>
	<brief_summary>This randomize double blind , double dummy , active comparator control , parallel design study perform assess safety efficacy BI 655066/ABBV-066 ( risankizumab ) compare adalimumab support registration treatment moderate severe chronic plaque psoriasis adult patient .</brief_summary>
	<brief_title>BI 655066/ABBV-066 ( Risankizumab ) Compared Active Comparator ( Adalimumab ) Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : Male female patient . Women childbearing potential* must ready able use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . *Women childbearing potential define : experienced menarche postmenopausal ( 12 month menses without alternative medical cause ) permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral oophorectomy bilateral salpingectomy ) . Age &gt; = 18 year screen Have diagnosis chronic plaque psoriasis ( without psoriatic arthritis ) least 6 month first administration study drug . Duration diagnosis may report patient . Have stable moderate severe chronic plaque psoriasis without psoriatic arthritis Screening Baseline ( Randomization ) : Have involve body surface area ( BSA ) &gt; = 10 % Have Psoriasis Area Severity Index ( PASI ) score &gt; = 12 Have static Physician Global Assessment ( sPGA ) score &gt; = 3 . Must candidate systemic therapy phototherapy psoriasis treatment , assessed investigator Must candidate treatment adalimumab ( Humira速 ) accord local label confirm investigator . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : Patients nonplaque form psoriasis ( include guttate , erythrodermic , pustular ) current druginduced psoriasis ( include exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) active ongoing inflammatory disease psoriasis might confound trial evaluation accord investigator 's judgment Previous exposure ABBV066 Previous exposure adalimumab ( Humira速 ) Currently enrol another investigational study le 30 day screen since complete another investigational drug device study . Use restricted medication drug consider likely interfere safe conduct study . Major surgery perform within 12 week prior randomization plan within 12 month screen ( e.g . hip replacement , removal aneurysm , stomach ligation ) . Known chronic relevant acute infection , active tuberculosis , HIV viral hepatitis ; QuantiFERON速 TB test PPD skin test perform accord local labelling Humira速 . If result positive , patient may participate study work ( accord local practice/guidelines ) establish conclusively patient evidence active tuberculosis . If presence latent tuberculosis establish , treatment initiate maintain accord local country guideline . Any documented active suspect malignancy history malignancy within 5 year prior screen , except appropriately treat basal cell squamous cell carcinoma skin situ carcinoma uterine cervix . Evidence current previous disease , medical condition ( include chronic alcohol drug abuse ) psoriasis , surgical procedure ( i.e. , organ transplant ) , medical examination finding ( include vital sign ECG ) , laboratory value Screening Visit outside reference range opinion investigator clinically significant would make study participant unreliable adhere protocol complete trial , compromise safety patient , compromise quality data . History allergy/hypersensitivity systemically administer biologic agent excipients Women pregnant , nursing , plan become pregnant trial Previous enrolment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Skin Diseases , Papulosquamous</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>Risankizumab</keyword>
</DOC>